Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab

Kolios, Antonios G A; Biedermann, Luc; Weber, Achim; Navarini, Alexander A; Meier, Jürg; Cozzio, Antonio; French, Lars E

doi:10.5167/uzh-144141

Citations

Citation copied

Kolios, A. G. A., Biedermann, L., Weber, A., Navarini, A. A., Meier, J., Cozzio, A., & French, L. E. (2018). Paradoxical ulcerative colitis during adalimumab treatment of psoriasis resolved by switch to ustekinumab. British Journal of Dermatology, 178, 551–555. https://doi.org/10.1111/bjd.15631

Abstract

Here we report the case of a patient with psoriasis who developed ulcerative colitis most likely caused by adalimumab. After cessation of adalimumab, colitis improved significantly. However, as psoriasis worsened, the patient was switched to ustekinumab, which resulted in complete cessation of colitis. During the 2-year follow-up under ustekinumab therapy, no further gastrointestinal complaints occurred. Paradoxical psoriasis manifestations in inflammatory bowel disease (IBD) under tumour necrosis factor (TNF)-inhibitor therapy have b